Core Viewpoint - Yifang Biotechnology experienced a decline of 5.09% in stock price, currently trading at 26.48 CNY per share, with a total market capitalization of 15.315 billion CNY [1] Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, and went public on July 25, 2022. The company is located in the China (Shanghai) Pilot Free Trade Zone [1] - The main business involves the research, production, and sales of innovative drugs, with 100% of its revenue derived from technology licensing and cooperation [1] Fund Holdings - Pengyang Fund has a significant holding in Yifang Biotechnology, with its Pengyang Medical Health Mixed A Fund (018052) holding 137,900 shares, accounting for 6.6% of the fund's net value, making it the second-largest holding [2] - The fund was established on October 31, 2023, with a latest scale of 22.571 million CNY and has achieved a year-to-date return of 39.01% [2] - The fund manager, Zhu Guoqing, has a tenure of 18 years and 221 days, with a total asset scale of 774 million CNY, while co-manager Cui Jieming has a tenure of 1 year and 359 days, managing 68.633 million CNY [2]